Brief: Silexion Therapeutics Announces Significant New Data From Phase 2 Trial Of Loder In Non-Resectable Pancreatic Cancer
24/09/2024 12:35
Sept 24 (Reuters) - Silexion Therapeutics Corp SLXN.O :
* SILEXION THERAPEUTICS ANNOUNCES SIGNIFICANT NEW DATA FROM
PHASE
2 TRIAL OF LODER™ IN NON-RESECTABLE PANCREATIC CANCER
* SILEXION THERAPEUTICS CORP - PROGRESSING WITH DEVELOPMENT
OF
NEXT-GEN PRODUCT SIL-204
Source text for Eikon: ID:nBw31f1tFa
Further company coverage: SLXN.O
((Reuters.Briefs@thomsonreuters.com;))